Crossmark

Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy

Crossref DOI link: https://doi.org/10.1186/s12885-024-13075-y

Published Online: 2024-11-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kearney, Mairead

Kirker, Melissa

Thompson, Allison

Gharibian, Norbek

Furegato, Martina

Pacheco, Cécile

Issa, Seham

Hasanova, Reyhan

Sciattella, Paolo

Scortichini, Matteo

Mennini, Francesco Saverio
License Information

Text and Data Mining valid from 2024-11-29

Version of Record valid from 2024-11-29
More Information

Article History

Received: 26 March 2024

Accepted: 17 October 2024

First Online: 29 November 2024

Declarations

:

: Retrospective studies using administrative databases do not require Ethics Committee protocol approval according to the rules of the Italian Medicines Agency (available at ).

: Not applicable.

: M. Kearney is an employee of Merck and has stock and other ownership interests in Merck, Novartis, and UCB. M. Kirker is an employee of, owns stock in, and has received honoraria from Pfizer. A. Thompson and N. Gharibian are employees and report stock and other ownership from Pfizer. M. Furegato, C. Pacheco, S. Issa, and R. Hasanova are employees of Oracle Life Sciences. Oracle Life Sciences received funding from Merck (CrossRef Funder ID: 10.13039/100009945) for the manuscript development. P. Sciattella, M. Scortichini, and F. Saverio Mennini declare no competing interests.

Document is current

Any future updates will be listed below